EUZ Eckert & Ziegler SE
Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration-related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.…
Industry Peers
Medical DevicesKey Statistics
About Eckert & Ziegler (ETR: EUZ)
›
Eckert & Ziegler (ETR: EUZ) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,131 employees.
The shares were at 14.75 EUR on 19 November 2026, down 8.3% over 52 weeks. Its 52-week range is 11.91 EUR to 16.84 EUR: the price is 12.4% below the high and 23.8% above the low.
At a market capitalisation of 923.05M EUR, it trades at 17.2 times trailing earnings and 16.9 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a discount of 33% for EUZ. It pays a dividend yielding 1.48% (it pays out 26% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
Eckert & Ziegler reports return on equity of 19.4%, an operating margin of 25.1% and revenue up 5.7% year over year.
It holds more cash than debt, a net cash position of 82.21M EUR. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.93 EUR is 48.7% above the current price. The next earnings report is expected on 24 March 2027.